News of mega-mergers involving the likes of Pfizer and Wyeth or Merck and Schering Plough have turned the pharmaceutical industry on its ear. But what does this mean for you and your patients? John Kreger, a principal with the health care investment bank William Blair & Company, tells the Chicago Tribune's Bruce Japsen about how consolidation among drug companies could impact doctors and their patients.
When Drug Companies Merge & the Effect on Your Practice

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
News of mega-mergers involving the likes of Pfizer and Wyeth or Merck and Schering Plough have turned the pharmaceutical industry on its ear. But what does this mean for you and your patients? John Kreger, a principal with the health care investment bank William Blair & Company, tells the Chicago Tribune's Bruce Japsen about how consolidation among drug companies could impact doctors and their patients.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?